Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2017 16:05 ET | Source: Radius Health Inc.

Radius Health Announces Commercial Leadership Changes with Appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and Promotion of Amanda Mott to Senior Vice President of Market Access

WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Joseph Kelly as Senior Vice President of Sales and...
November 02, 2017 16:01 ET | Source: Radius Health Inc.

Radius Health Reports Third Quarter 2017 Financial and Operating Results and Provides Business Update

First full quarter of TYMLOS™ sales shows accelerating market share & stabilization of the anabolic market Plan access at approximately 200 million lives – 87% commercial and 35% Medicare Male...
October 18, 2017 09:00 ET | Source: Radius Health Inc.

Radius Health Receives FDA Fast Track Designation for Elacestrant (RAD1901)

- Radius plans to initiate Phase 2 clinical study of elacestrant as a third-line therapy for women with ER+ and HER2- breast cancer early in 2018 - - Phase 2 Study is a potentially pivotal trial for...
October 13, 2017 08:00 ET | Source: Radius Health Inc.

Radius Health to Present First Health Economics Data on TYMLOS™ (abaloparatide) Injection at the Academy of Managed Care Pharmacy Nexus 2017

Five posters will cover new data on the need for osteoporosis awareness as well as cost-effectiveness data on treatment with TYMLOS WALTHAM, Mass., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Radius Health,...
October 09, 2017 09:00 ET | Source: Radius Health Inc.

Radius Health to Announce Third Quarter 2017 Financial Results, Host Conference Call and Live Webcast on November 2, 2017

WALTHAM, Mass., Oct. 09, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The Company...
September 29, 2017 08:45 ET | Source: Radius Health Inc.

Radius Health Initiates Phase 1 Clinical Trial of RAD140 for the Treatment of Hormone Receptor Positive Breast Cancer

WALTHAM, Mass., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that the first patient has been enrolled in the company’s Phase 1 study of RAD140, a nonsteroidal...
September 22, 2017 16:06 ET | Source: Radius Health Inc.

Radius Health to Present at Cantor Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing...
September 10, 2017 13:30 ET | Source: Radius Health Inc.

Radius Health Presents Positive Data for TYMLOS™ (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR 2017 Annual Meeting

ACTIVExtend trial demonstrated statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by alendronate WALTHAM, Mass., Sept. 10, 2017 (GLOBE...
September 07, 2017 07:00 ET | Source: Radius Health Inc.

Radius Health to Present at Morgan Stanley 15th Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing and commercializing...
September 01, 2017 14:00 ET | Source: Radius Health Inc.

Radius Health to Present Eight Abstracts at the American Society of Bone and Mineral Research (ASBMR) 2017 Annual Meeting Including Results of the ACTIVE and ACTIVExtend Trials for TYMLOS™ (abaloparatide) Injection

Results from the ACTIVExtend trial, which demonstrated statistically significant fracture risk reduction at 3.5 years of sequential therapy – TYMLOS followed by alendronate – will be presented in an...